Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Jessica S Brown"'
Autor:
Melanie A. Jones, Kirsten M. Timms, Shanell Hatcher, Elizabeth S. Cogan, Matthew S. Comeaux, Michael Perry, Brian Morris, Brad Swedlund, Cathy E. Elks, Pierre Lao‐Sirieix, Simon Dearden, Coumaran Egile, Jessica S. Brown, Elizabeth A. Harrington, Darren Hodgson, Matt Stern, Thomas P. Slavin, Debora Mancini‐DiNardo
Publikováno v:
Genes, Chromosomes and Cancer.
Autor:
Udai Banerji, Michelle D. Garrett, Florence I. Raynaud, Karen E. Swales, Sarah Mellor, Gavin Halbert, Stephanie Traub, Paul Jones, Victoria Sanz-Moreno, Oscar Maiques, Roberta Ferraldeschi, Simone Jueliger, Shaun Decordova, Ruth Ruddle, Alvaro H. Ingles Garces, Jessica S. Brown, Joaquin Mateo, Dionysis Papadatos-Pastos, Rajiv Kumar, Robert McLeod
Purpose:AT13148 is an oral AGC kinase inhibitor, which potently inhibits ROCK and AKT kinases. In preclinical models, AT13148 has been shown to have antimetastatic and antiproliferative activity.Patients and Methods:The trial followed a rolling six d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a333c1f82c5ff3931176d17bb6ff2c
https://doi.org/10.1158/1078-0432.c.6529065.v1
https://doi.org/10.1158/1078-0432.c.6529065.v1
Autor:
Udai Banerji, Michelle D. Garrett, Florence I. Raynaud, Karen E. Swales, Sarah Mellor, Gavin Halbert, Stephanie Traub, Paul Jones, Victoria Sanz-Moreno, Oscar Maiques, Roberta Ferraldeschi, Simone Jueliger, Shaun Decordova, Ruth Ruddle, Alvaro H. Ingles Garces, Jessica S. Brown, Joaquin Mateo, Dionysis Papadatos-Pastos, Rajiv Kumar, Robert McLeod
Inclusion/Exclusion Criteria and Pharmacokinetic Analytical Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5127ad704e76e04993609e6ace90960e
https://doi.org/10.1158/1078-0432.22475382
https://doi.org/10.1158/1078-0432.22475382
Autor:
Udai Banerji, Michelle D. Garrett, Florence I. Raynaud, Karen E. Swales, Sarah Mellor, Gavin Halbert, Stephanie Traub, Paul Jones, Victoria Sanz-Moreno, Oscar Maiques, Roberta Ferraldeschi, Simone Jueliger, Shaun Decordova, Ruth Ruddle, Alvaro H. Ingles Garces, Jessica S. Brown, Joaquin Mateo, Dionysis Papadatos-Pastos, Rajiv Kumar, Robert McLeod
Relationship between dose and AUC/Cmax
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::680ddacf31e0bd6d533d55ce226c23b9
https://doi.org/10.1158/1078-0432.22475379
https://doi.org/10.1158/1078-0432.22475379
Autor:
Udai Banerji, Michelle D. Garrett, Florence I. Raynaud, Karen E. Swales, Sarah Mellor, Gavin Halbert, Stephanie Traub, Paul Jones, Victoria Sanz-Moreno, Oscar Maiques, Roberta Ferraldeschi, Simone Jueliger, Shaun Decordova, Ruth Ruddle, Alvaro H. Ingles Garces, Jessica S. Brown, Joaquin Mateo, Dionysis Papadatos-Pastos, Rajiv Kumar, Robert McLeod
Demographic Profile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5956b87f62609112cab6983b09499bd
https://doi.org/10.1158/1078-0432.22475376.v1
https://doi.org/10.1158/1078-0432.22475376.v1
Autor:
Jessica S. Brown, Natalia Lukashchuk, Matylda Sczaniecka-Clift, Sébastien Britton, Carlos le Sage, Patrick Calsou, Petra Beli, Yaron Galanty, Stephen P. Jackson
Publikováno v:
Cell Reports, Vol 11, Iss 5, Pp 704-714 (2015)
The activities of many DNA-repair proteins are controlled through reversible covalent modification by ubiquitin and ubiquitin-like molecules. Nonhomologous end-joining (NHEJ) is the predominant DNA double-strand break (DSB) repair pathway in mammalia
Externí odkaz:
https://doaj.org/article/f06df8c07f7b4bd88088d1b4e5907bb3
Autor:
Arun Azad, Mark Voskoboynik, Ana Filipa Palma dos Reis, Anthony M. Joshua, Andrew James Weickhardt, Robert J. Jones, Pasquale Rescigno, Ben Tran, Caroline Kennedy, Spiros Linardopoulos, Ganesh Moorthy, TJ Zhou, Jessica S Brown, Edit Lukacs, Richard Francis, Andrew Hudson
Publikováno v:
Journal of Clinical Oncology. 41:TPS296-TPS296
TPS296 Background: AZD5305 is a potent and selective oral PARP inhibitor (PARPi) that specifically targets and traps PARP1, in contrast to approved PARPis which target both PARP1 and PARP2. Preclinical data suggest that PARP1 inhibition confers antip
Autor:
Nina Tunariu, Raquel Perez-Lopez, Maria Jose de Miguel Luken, Brian Hare, Udai Banerji, Daniel Nava Rodrigues, Katherine McDermott, Timothy A. Yap, Juanita Lopez, Stephen J. Pettitt, Ines Figueiredo, Chris T. Williamson, Johann S. de Bono, Jessica S. Brown, Ruth Riisnaes, Rachael Natrajan, Brent O’Carrigan, Saira Khalique, Joline S. Lim, John Pollard, Marina Penney, Christopher J. Lord, Suzanne Carreira
Publikováno v:
Journal of Clinical Oncology
PURPOSE Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplati
Autor:
Jessica S. Brown, Stephen P. Jackson
Publikováno v:
Open Biology, Vol 5, Iss 4 (2015)
Failure of accurate DNA damage sensing and repair mechanisms manifests as a variety of human diseases, including neurodegenerative disorders, immunodeficiency, infertility and cancer. The accuracy and efficiency of DNA damage detection and repair, co
Externí odkaz:
https://doaj.org/article/4803a4971fae4c0780c0ea4c8bbff686
Autor:
Zhongwu Lai, Darren Hodgson, Brian Dougherty, J. Carl Barrett, Tsveta Milenkova, Elizabeth A. Harrington, Jessica S Brown, Eric Pujade-Lauraine, Simon Dearden, Alexandra Leary, Jerry S. Lanchbury, Michael C. Perry, Cathy E. Elks, Kirsten Timms
Publikováno v:
Gynecologic oncology. 163(3)
Objective Maintenance olaparib provided a progression-free survival benefit in the phase III SOLO2 trial (NCT01874353) in patients with platinum-sensitive relapsed ovarian cancer and a BRCA mutation (BRCAm). However, questions remain regarding tumor